Kanatsuka, "Five missense mutations in glucagonlike peptide
1 receptor gene in Japanese population," Diabetes Research and Clinical Practice, vol.
2 enhances small intestinal absorptive function and mucosal mass in vivo.
Protein processing is also the target of therapeutic interventions such as use of dipeptidyl-peptidase IV (DPP-IV) inhibitors, which inhibit protease processing of glucagonlike peptide
1 and glucose-dependent insulinotropic peptide in treatment of diabetes (21-23).
The novel glucagonlike peptide
1 (GLP-1) receptor agonist semaglutide may reduce the risk of cardiovascular events in patients with type 2 diabetes who are at elevated cardiovascular risk, according to data presented at the annual meeting of the European Association for the Study of Diabetes and simultaneously published online in the New England Journal of Medicine.
Nausea, the most troublesome side effect of any glucagonlike peptide
receptor agonist, occurred in 12% of those taking the drug.
BOSTON--The glucagonlike peptide
1 (GLP-1) receptor agonist lixisenatide does not increase the risk for cardiovascular diseases in diabetic patients, according to findings from the first cardiovascular disease outcomes trial for this widely prescribed class of glucose-lowering drugs.
Liraglutide, a human glucagonlike peptide
1 (GLP-1) receptor agonist that promotes glucose-dependent insulin secretion, will be marketed by Novo Nordisk under the name Victoza.